Clinical trials: Impulse Control Disorders
- Condition Impulse Control Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Impulse Control Disorders
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
- Trial name
- NCT03887429
- Testing
- SXC-2023
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Promentis Pharmaceuticals, Inc.
Trichotillomania
Feasibility Study for Treating Trichotillomania With Wearable Device and App System
Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop.
- Trial name
- NCT04241120
- Testing
- Device and app system designed for participant to self-administer Habit Reversal Training, Reminder bracelet control condition
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HabitAware Inc.
Intermittent Explosive Disorder
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).
- Trial name
- AVN009 (NCT02055638)
- Testing
- SRX246
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Azevan Pharmaceuticals
Atrial Fibrillation
Topera C-FIRM Registry
This is a control registry to the E-FIRM registry to track conventional atrial fibrillation (AF) procedures in terms of clinical usage, handling, and the safety and effectiveness for the treatment of symptomatic atrial…
- Trial name
- NCT02407249
- Where
- 9 sites in Germany, Netherlands
- Volunteers
- 73 people
- Sponsor
- Abbott Medical Devices
Pathological Gambling
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
- Trial name
- NCT01215357
- Testing
- Ecopipam
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Emalex Biosciences Inc.
Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
- Trial name
- NCT03420222
- Testing
- AVP-786
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.